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Hypokalemic paralysis is a rare condition 
characterized by episodic weakness associated 
with hypokalemia.1 Several disorders have been 
associated with hypokalemic paralysis. However, 
most cases are due to renal tubular acidosis 
(RTA).2 RTA is suspected in the presence of 
hyperchloremic metabolic acidosis (HMA) and 
it is divided into three categories: proximal 
RTA, distal RTA (dRTA), and hyperkalemic 
RTA. dRTA is characterized by the inability to 
excrete the daily acid loads and by potassium 
imbalances.3 Primary Sjögren’s syndrome (pSS) 
mainly affects exocrine glands; nevertheless 
it can impair renal function via tubular and 
glomerular injury.4 In adults, pSS has been 
identified as the leading cause of acquired 
dRTA.5 The relevance of this case stands in the 
atypical clinical presentation of symptomatic, 
severe hypokalemia as the first manifestation 
of pSS.
CASE REPORT
A 38-year-old female patient presented to the 
emergency department with a three-day history 
of dyspnea and progressive quadriparesis. This 
weakness progressed over a day until she was 
unable to stand up. She also reported fatigue 
and occasional acroparesthesias. On physical 
examination, she was alert and reactive, but 
unable to move any limb; she also was tachypneic 
and incapable to talk. Her blood pressure was 
120/80 mmHg and her oxygen saturation 
was 97% at room air. Chest and abdominal 
examinations were noncontributory. Deep tendon 
reflexes were absent and strength was 0/5 in all 
four limbs, according to Medical Research Council 
scale. No Babinski response was found.
Level of serum potassium was 1.9 mmol/L, 
sodium was 138 mmol/L, chloride was 
116.1 mmol/L, total serum calcium was 8.6 mg/dL, 
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and serum albumin was 4.2 g/dL. The arterial blood 
gas analysis revealed a pH of 7.12, partial pressure 
of carbon dioxide of 37 mmHg, and bicarbonate 
of 12.0 mEq/L. Her erythrocyte sedimentation 
rate was 12 mm/hour. Urinalysis showed a pH 
of 8.0 without proteinuria, leukocyturia, or other 
alteration. Urinary sodium was 103 mmol/L, 
urinary potassium was 30 mmol/L, and urinary 
chloride was 57.3 mmol/L. Her urine potassium-
creatinine ratio was 4.1 and her fractional excretion 
of potassium was 20%. She also had a urinary 
anion gap of 76 mmol/L and a 24-hour urinary 
calcium of 449.8 mmol. Renal ultrasound revealed 
bilateral nephrocalcinosis. The rest of the laboratory 
tests were within the normal range (e.g., serum 
creatinine, liver function tests, thyroid function 
tests, enzyme-linked immunosorbent assay for 
human immunodeficiency virus, hepatitis B surface 
antigen, and anti-hepatitis C virus).
We established the diagnosis of dRTA. 
A central venous catheter was then placed 
and she was started on intravenous potassium 
chloride and sodium bicarbonate. She clinically 
improved and her acid-base balance was 
restored. The patient was later switched to 
oral potassium citrate and remained solely on 
it. The most common causes of dRTA were 
rationally excluded. The remaining etiologies 
were autoimmune diseases, including systemic 
erythematous lupus, rheumatoid arthritis, and 
pSS. There was no history of fever, joint pain, 
skin rash, photosensibility, xerostomy, or parotid 
swelling. Her Schirmer's test was normal but she 
was positive for antinuclear antibodies (1:5120, 
SS A/Ro pattern). Thereafter, we tested her for 
specific anti-SS B/La and anti-SS A/Ro, and she 
was also positive (19 and 200 U/mL, respectively). 
Due to the lack of typical presentation, we 
performed a salivary gland biopsy and thus 
diagnosed pSS according to the American 
College of Rheumatology/Sjögren's International 
Collaborative Clinical Alliance criteria. The 
patient was later discharged on potassium citrate 
and hydroxychloroquine. Before reporting her 
case, a written informed consent was obtained 
from the patient.
DISCUSSION
Hypokalemic paralysis is a rare disorder 
characterized by potentially fatal episodes of muscle 
weakness associated with hypokalemia, which 
can affect the respiratory muscles.2 Hypokalemic 
paralyses are divided into primary and secondary 
forms. Secondary forms are more common and 
are the result of acquired hypokalemia such 
as thyrotoxicosis, hyperaldosteronism, diabetic 
ketoacidosis, diarrhea, vomiting, drugs or RTA.6 
The term RTA is applied to a group of defects in 
bicarbonate reabsorption, hydrogen ion excretion, 
or both. It is distinguished by a relatively normal 
glomerular filtration rate and a HMA. dRTA is 
characterized by impaired hydrogen ion secretion 
in the distal part of the nephron; this defect, in 
its severe form, leads to an inability to excrete the 
daily acid load, resulting in progressive hydrogen 
ion retention and a HMA.7 Although diminished 
H+-ATPase activity is probably the most common 
defect in dRTA, impaired hydrogen ion secretion 
may be caused by several defects.8 dRTA is 
commonly associated with hypokalemia due to 
renal wasting.6 Occasionally, this hypokalemia 
is sufficiently severe to produce paralysis or 
respiratory arrest.9 In adults, autoimmune diseases 
are major causes of dRTA,3 and this may be 
its presenting manifestation. Thus, adults with 
apparently idiopathic dRTA should be evaluated 
for these conditions.8
Distal RTA occurs in up to 5% of patients with 
pSS; however, the prevalence of symptomatic 
dRTA was not assessed in this study. The 
first case secondary to pSS was reported by 
Shern and Tu10 in 1965. The mechanism by 
which pSS leads to dRTA is incompletely 
understood.11 One explanation has been found in 
immunocytochemical analyses of renal biopsies 
which have shown complete absence of H-ATPase 
pumps in the intercalated cell of the collecting 
tubules which is largely responsible for proton 
secretion.12 Another possible mechanism is the 
presence of high titers of an autoantibody directed 
against carbonic anhydrase II. Inhibition of this 
enzyme would be expected to impair intracellular 
generation of hydrogen ions.13
Sjögren's syndrome is among the most 
frequent systemic autoimmune diseases. Its 
main clinical features are ocular and oral 
dryness.14 Systemic complications can occur in 
pSS, and approximately 10% of patients have 
renal involvement.4 Some studies correlated 
RTA and high anti-SS A/Ro and anti-SS B/La 
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level titers as a surrogate of pSS progression.15,16 
Additionally, other studies have suggested that 
lymphoplasmacytic infiltrates surrounding 
renal tubules are associated with renal tubular 
defects.17
It is recommended to treat dRTA with 
potassium citrate, which is an effective treatment 
for both the symptoms and complications of dRTA 
by restoring acid-base balance. It is unknown 
whether treatment with steroids has a positive 
effect on autoimmune dRTA.8
The clinical presentation of hypokalemic 
quadriparesis with respiratory failure as the first 
manifestation of pSS is very atypical. In this 
article, we tried to emphasize that hypokalemia 
can precipitate severe muscular weakness, and 
also that further evaluations are usually needed in 
order to elucidate the etiology of HMA.
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